Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels
- 7 November 2006
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 48 (9) , 1774-1781
- https://doi.org/10.1016/j.jacc.2006.06.067
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*Current Medical Research and Opinion, 2004
- Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.Atherosclerosis, 2003
- benefit-risk assessment of Rosuvastatin 10 to 40 milligramsThe American Journal of Cardiology, 2003
- Cholesteryl Ester Transfer ProteinArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Proatherogenic Role of Elevated CE Transfer From HDL to VLDL 1 and Dense LDL in Type 2 DiabetesArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbitsNature, 2000
- Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed RabbitsJournal of Biological Chemistry, 1998
- Heterogeneity of plasma low-density lipoproteins and atherosclerosis riskCurrent Opinion in Lipidology, 1994
- Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice.Journal of Clinical Investigation, 1993